Home > Cardiology > AHA 2020 > Miscellaneous > Mavacamten effective in obstructive hypertrophic cardiomyopathy

Mavacamten effective in obstructive hypertrophic cardiomyopathy

Presented By
Dr Sheila Hegde, Brigham and Women’s Hospital, USA
Conference
AHA 2020
Trial
Phase 3, EXPLORER-HCM

Results from the multicentre, phase 3 EXPLORER-HCM trial highlight the benefits of a disease-specific treatment for patients with obstructive hypertrophic cardiomyopathy. Mavacamten, a first-in-class cardiac myosin inhibitor, improved exercise capacity, left ventricular outflow tract (LVOT) obstruction, NYHA functional class, and health status in this patient population [1,2].

Dr Sheila Hegde (Brigham and Women's Hospital, USA) presented the results of the randomised, double-blind, placebo-controlled phase 3 EXPLORER-HCM trial (NCT03470545). This study evaluated the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy with a LVOT gradient of ≥50 mmHg and NYHA class II-III symptoms. Participants from 68 centres in 13 countries were randomly assigned to mavacamten 5 mg daily (n=123) or placebo (n=128) for 30 weeks. The primary endpoint was a...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on